JP2022517216A5 - - Google Patents
Info
- Publication number
- JP2022517216A5 JP2022517216A5 JP2021540076A JP2021540076A JP2022517216A5 JP 2022517216 A5 JP2022517216 A5 JP 2022517216A5 JP 2021540076 A JP2021540076 A JP 2021540076A JP 2021540076 A JP2021540076 A JP 2021540076A JP 2022517216 A5 JP2022517216 A5 JP 2022517216A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- fragment
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910022548.9 | 2019-01-10 | ||
| CN201910022548.9A CN111423510B (zh) | 2019-01-10 | 2019-01-10 | 重组抗人pd-1抗体及其应用 |
| PCT/CN2020/071353 WO2020143749A1 (zh) | 2019-01-10 | 2020-01-10 | 重组抗人pd-1抗体及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022517216A JP2022517216A (ja) | 2022-03-07 |
| JP2022517216A5 true JP2022517216A5 (https=) | 2023-01-20 |
Family
ID=71521975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540076A Pending JP2022517216A (ja) | 2019-01-10 | 2020-01-10 | 組換え抗ヒトｐｄ－１抗体およびその用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230104769A1 (https=) |
| EP (1) | EP3919514A4 (https=) |
| JP (1) | JP2022517216A (https=) |
| KR (1) | KR20210113635A (https=) |
| CN (1) | CN111423510B (https=) |
| CA (1) | CA3126302A1 (https=) |
| TW (1) | TW202043271A (https=) |
| WO (1) | WO2020143749A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022012428A1 (zh) * | 2020-07-14 | 2022-01-20 | 迈威(上海)生物科技股份有限公司 | 抗pd-1抗体及其稳定制剂 |
| KR20220082775A (ko) * | 2020-12-10 | 2022-06-17 | 주식회사 유틸렉스 | 항-pd-1 항체 및 이의 용도 |
| CN115925954A (zh) * | 2022-12-28 | 2023-04-07 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途 |
| WO2025102227A1 (zh) * | 2023-11-14 | 2025-05-22 | 成都盛世君联生物技术有限公司 | 一种抗pd-1抗体及其生物材料和产品 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| BR112017001385B1 (pt) * | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc. | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão |
| CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| HUE068868T2 (hu) * | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| US10981991B2 (en) * | 2015-09-29 | 2021-04-20 | Shanghai Zhangjiang Biotechnology Co., Ltd. | PD-1 antibodies and uses thereof |
| CN106632674B (zh) * | 2015-10-30 | 2018-11-16 | 泽达生物医药有限公司 | 一种抗pd-1单克隆抗体、其药物组合物及其用途 |
| CN106699889A (zh) * | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | 抗pd-1抗体及其治疗用途 |
| JP7003036B2 (ja) * | 2015-12-02 | 2022-02-04 | エスティーキューブ，インコーポレイテッド | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
| CN108079292A (zh) * | 2016-11-23 | 2018-05-29 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 |
| CN107446048B (zh) * | 2017-09-13 | 2021-03-30 | 北京韩美药品有限公司 | 一种能够特异性地结合pd-1的抗体及其功能片段 |
| CN108218988B (zh) * | 2017-11-29 | 2019-10-11 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用 |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| WO2020252418A2 (en) * | 2019-06-14 | 2020-12-17 | Cugene, Inc. | Novel interleukin-2 variants for the treatment of cancer |
| JP7807076B2 (ja) * | 2019-12-13 | 2026-01-27 | キュージーン インコーポレイテッド | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
| MX2022007202A (es) * | 2019-12-13 | 2022-10-07 | Cugene Inc | Fármacos bioactivables a base de citocinas y metodos de uso de los mismos. |
-
2019
- 2019-01-10 CN CN201910022548.9A patent/CN111423510B/zh active Active
-
2020
- 2020-01-09 TW TW109100705A patent/TW202043271A/zh unknown
- 2020-01-10 EP EP20738344.9A patent/EP3919514A4/en not_active Withdrawn
- 2020-01-10 WO PCT/CN2020/071353 patent/WO2020143749A1/zh not_active Ceased
- 2020-01-10 US US17/422,123 patent/US20230104769A1/en not_active Abandoned
- 2020-01-10 JP JP2021540076A patent/JP2022517216A/ja active Pending
- 2020-01-10 KR KR1020217024728A patent/KR20210113635A/ko not_active Ceased
- 2020-01-10 CA CA3126302A patent/CA3126302A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102068600B1 (ko) | Pdl-1 항체, 그 약학적 조성물 및 그 용도 | |
| JP2021527431A5 (https=) | ||
| JP7785284B2 (ja) | Ｃｄ３８抗体とｉｃａｍ１抗体およびそれらの使用 | |
| RU2019141289A (ru) | АНТИ-SIRPα АНТИТЕЛА | |
| CN113454119B (zh) | 抗btla抗体 | |
| JP2017535257A5 (https=) | ||
| JP2021533726A5 (https=) | ||
| JP2020520370A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| JP2019536470A5 (https=) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2020514277A5 (https=) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2021524256A5 (https=) | ||
| JP2011509245A5 (https=) | ||
| JP2016536020A5 (https=) | ||
| JP2022517216A5 (https=) | ||
| JP2018510617A5 (https=) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2024541680A5 (https=) | ||
| JP2022553922A5 (https=) | ||
| JP2023518153A5 (https=) | ||
| JP2017521054A5 (https=) | ||
| JP2024540148A5 (https=) |